Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor [PDF]
Journal of Inflammation Research, 2023 Yan Teng,1 Yibin Fan,1 Danying Shang,1 Xiaohua Tao,1,* Dongsheng Sun2,* 1Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou ...
Teng Y, Fan Y, Shang D, Tao X, Sun D
doaj +3 more sources
Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal? [PDF]
Front Immunol, 2022 Alopecia universalis (AU) is an autoimmune disorder characterized by non-scarring hair loss in the scalp, eyebrows, beard, and nearly the entire body, negatively affecting patient prognosis. Available treatments are usually unsatisfactory. The autoimmune
Yu L, Yu H, Zhang S, Hao Y, Zhang S.
europepmc +4 more sources
Alopecia universalis after injection of messenger RNA COVID-19 vaccine. A case report [PDF]
IDCases, 2023 Messenger RNA vaccines against SARS-CoV-2 infection, or COVID-19 dramatically changed the landscape of the fight against COVID-19 pandemic. However, they might be associated with various side effects, such as myocarditis.
Kentaro Iwata, Makoto Kunisada
doaj +3 more sources
Diphenylcyclopropenone-Induced Vitiligo in a Patient with Alopecia Universalis [PDF]
Case Reports in Dermatology, 2013 Alopecia areata and vitiligo are autoimmune diseases, both associated with multiple autoimmune comorbidities. Many studies show colocalization of these diseases at the same anatomical site.
Hassan Riad +6 more
doaj +6 more sources
Successful Therapy of Alopecia Universalis Using a Combination of Systemic Methotrexate and Corticosteroids and Topical 5% Minoxidil [PDF]
Clinical, Cosmetic and Investigational Dermatology, 2022 Kartika Ruchiatan, Erda Avriyanti, Reti Hindritiani, Diah Puspitosari, Oki Suwarsa, Hendra Gunawan Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr.
Ruchiatan K +5 more
doaj +3 more sources
Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis. [PDF]
CureusObjectives Tofacitinib, an effective Janus kinase inhibitor (JAKi), has gained increasing interest in recent years for the management of refractory alopecia areata (AA). One of the most prevalent autoimmune diseases is AA, a kind of non-scarring alopecia.
Tirmizi SS +3 more
europepmc +4 more sources
Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis [PDF]
Frontiers in MedicineBackgroundAlopecia areata (AA) is a chronic immune-mediated disorder causing non-scarring hair loss. Severe forms like alopecia totalis (AT) and alopecia universalis (AU) pose therapeutic difficult situations.
Taiyo Hitaka +6 more
doaj +3 more sources
Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222). [PDF]
JAAD Case Rep, 2022 Ho JD +4 more
europepmc +3 more sources
Effective treatment of alopecia universalis with oral upadacitinib. [PDF]
JAAD Case Rep, 2023 Youssef S, Bordone LA.
europepmc +5 more sources
Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata. [PDF]
Dermatol Ther (Heidelb), 2023 Alopecia areata (AA) is a cell-mediated autoimmune disease in which a cytotoxic T-cell response against hair follicles occurs. AA has been demonstrated to frequently co-exist with atopic dermatitis (AD), and the coincidence of atopy predisposes to a more
Kołcz K +3 more
europepmc +2 more sources